替吉奥联合奥沙利铂方案治疗老年胃癌对患者血清肿瘤标志物、基质金属蛋白酶及免疫功能的影响

Effect of S-1 combined with oxaliplatin on serum tumor markers,matrix metalloproteinase and immune function in elderly patients with gastric cancer

目的:探讨替吉奥联合奥沙利铂化疗对老年胃癌患者血清肿瘤标志物,基质金属蛋白酶及免疫功能的影响。方法:将80例老年胃癌患者随机分为对照组和观察组(每组40例),对照组给予卡培他滨片联合奥沙利铂方案,观察组患者给予替吉奥联合奥沙利铂方案,两组均治疗6个周期,比较治疗前后两组血清肿瘤标志物、基质金属蛋白酶及免疫功能水平。结果:治疗前,两组CEA、CA125、CA19-9、MMP-2、MMP-9、CD3^+、CD4^+、CD8^+、CD4^+/CD8^+水平比较,差异无统计学意义(P>0.05);治疗后,两组CEA、CA125、CA19-9、MMP-2、MMP-9、CD8^+水平均显著低于组内治疗前,且观察组CEA、CA125、CA19-9、MMP-2、MMP-9、CD8^+水平显著低于对照组,差异有统计学意义(P<0.05);与组内治疗前相比,两组治疗后CD3^+、CD4^+、CD4^+/CD8^+水平均显著升高,观察组治疗后水平均显著高于对照组,差异有统计学意义(P<0.05)。结论:替吉奥与奥沙利铂联合化疗可有效降低老年胃癌患者血清肿瘤标志物及基质金属蛋白酶水平,改善免疫功能,具有重要临床价值。

Objective:To investigate the effect of Compound Tegafur and Oteracil Potassium Sustained Capsules(S-1)combined with oxaliplatin chemotherapy on serum tumor marker matrix metalloproteinase and immune function in elderly patients with gastric cancer.Methods:According to the random data table,80cases of elderly patients with gastric cancer were divided into control group and observation group(n=40),patients in the control group were treated with oxaliplatin combined with Capecitabine Tablets,and the observation group patients were treated with S-1combined with oxaliplatin,all treated for6cycles,before and after treatment,levels of serum tumor markers,matrix metalloproteinase and immune function were compared between the two groups.Results:Before treatment,there was no significant difference in the levels of CEA,CA125,CA19-9,MMP-2,MMP-9,CD3+,CD4+,CD8+and CD4+/CD8+between the two groups(P>0.05);After treatment,the levels of CEA,CA125,CA19-9,MMP-2,MMP-9and CD8+in the two groups were significantly lower than those in the same group before treatment,and the levels of the observation group[(7.79±2.78)ng/ml,(22.56±7.31)U/mL,(13.48±3.05)U/mL,(57.84±8.93)ng/mL,(199.14±67.39)ng/mL and(26.21±4.18)%]were significantly lower than those in the control group(P<0.05);Compared with the group before treatment,the levels of CD3+,CD4+and CD4+/CD8+in the two groups were significantly increased,and the observation group[(66.89±5.84)%,(41.63±5.24)%and(1.37±0.29)]was significantly higher than the control group(all P<0.05).Conclusion:S-1combined with oxaliplatin chemotherapy can effectively reduce serum tumor markers and matrix metalloproteinase levels,improve immune function,has an important clinical value.